Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

G. L. Uy, L. J. Costa, P. N. Hari, M. J. Zhang, J. X. Huang, K. C. Anderson, C. N. Bredeson, N. S. Callander, R. F. Cornell, M. A.D. Perez, A. Dispenzieri, C. O. Freytes, R. P. Gale, A. Garfall, M. A. Gertz, J. Gibson, M. Hamadani, H. M. Lazarus, M. E. Kalaycio, R. T. KambleM. A. Kharfan-Dabaja, A. Y. Krishnan, S. K. Kumar, R. A. Kyle, H. J. Landau, C. H. Lee, A. Maiolino, D. I. Marks, T. M. Mark, R. Munker, T. Nishihori, R. F. Olsson, M. Ramanathan, T. E. Rodriguez, A. A. Saad, B. N. Savani, G. J. Schiller, H. C. Schouten, J. R. Schriber, Emma Scott, S. Seo, M. Sharma, S. Ganguly, E. A. Stadtmauer, J. Tay, L. B. To, D. H. Vesole, D. T. Vogl, J. L. Wagner, B. Wirk, W. A. Wood, A. D'Souza

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

Original languageEnglish (US)
Pages (from-to)1513-1518
Number of pages6
JournalBone marrow transplantation
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Cell Transplantation
Multiple Myeloma
Intercellular Signaling Peptides and Proteins
Drug Therapy
Confidence Intervals
Transplants
Canada
Blood Cells
Neutrophils
Stem Cells
Blood Platelets
Bone Marrow
Databases
Research

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. / Uy, G. L.; Costa, L. J.; Hari, P. N.; Zhang, M. J.; Huang, J. X.; Anderson, K. C.; Bredeson, C. N.; Callander, N. S.; Cornell, R. F.; Perez, M. A.D.; Dispenzieri, A.; Freytes, C. O.; Gale, R. P.; Garfall, A.; Gertz, M. A.; Gibson, J.; Hamadani, M.; Lazarus, H. M.; Kalaycio, M. E.; Kamble, R. T.; Kharfan-Dabaja, M. A.; Krishnan, A. Y.; Kumar, S. K.; Kyle, R. A.; Landau, H. J.; Lee, C. H.; Maiolino, A.; Marks, D. I.; Mark, T. M.; Munker, R.; Nishihori, T.; Olsson, R. F.; Ramanathan, M.; Rodriguez, T. E.; Saad, A. A.; Savani, B. N.; Schiller, G. J.; Schouten, H. C.; Schriber, J. R.; Scott, Emma; Seo, S.; Sharma, M.; Ganguly, S.; Stadtmauer, E. A.; Tay, J.; To, L. B.; Vesole, D. H.; Vogl, D. T.; Wagner, J. L.; Wirk, B.; Wood, W. A.; D'Souza, A.

In: Bone marrow transplantation, Vol. 50, No. 12, 01.12.2015, p. 1513-1518.

Research output: Contribution to journalArticle

Uy, GL, Costa, LJ, Hari, PN, Zhang, MJ, Huang, JX, Anderson, KC, Bredeson, CN, Callander, NS, Cornell, RF, Perez, MAD, Dispenzieri, A, Freytes, CO, Gale, RP, Garfall, A, Gertz, MA, Gibson, J, Hamadani, M, Lazarus, HM, Kalaycio, ME, Kamble, RT, Kharfan-Dabaja, MA, Krishnan, AY, Kumar, SK, Kyle, RA, Landau, HJ, Lee, CH, Maiolino, A, Marks, DI, Mark, TM, Munker, R, Nishihori, T, Olsson, RF, Ramanathan, M, Rodriguez, TE, Saad, AA, Savani, BN, Schiller, GJ, Schouten, HC, Schriber, JR, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, EA, Tay, J, To, LB, Vesole, DH, Vogl, DT, Wagner, JL, Wirk, B, Wood, WA & D'Souza, A 2015, 'Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation', Bone marrow transplantation, vol. 50, no. 12, pp. 1513-1518. https://doi.org/10.1038/bmt.2015.190
Uy, G. L. ; Costa, L. J. ; Hari, P. N. ; Zhang, M. J. ; Huang, J. X. ; Anderson, K. C. ; Bredeson, C. N. ; Callander, N. S. ; Cornell, R. F. ; Perez, M. A.D. ; Dispenzieri, A. ; Freytes, C. O. ; Gale, R. P. ; Garfall, A. ; Gertz, M. A. ; Gibson, J. ; Hamadani, M. ; Lazarus, H. M. ; Kalaycio, M. E. ; Kamble, R. T. ; Kharfan-Dabaja, M. A. ; Krishnan, A. Y. ; Kumar, S. K. ; Kyle, R. A. ; Landau, H. J. ; Lee, C. H. ; Maiolino, A. ; Marks, D. I. ; Mark, T. M. ; Munker, R. ; Nishihori, T. ; Olsson, R. F. ; Ramanathan, M. ; Rodriguez, T. E. ; Saad, A. A. ; Savani, B. N. ; Schiller, G. J. ; Schouten, H. C. ; Schriber, J. R. ; Scott, Emma ; Seo, S. ; Sharma, M. ; Ganguly, S. ; Stadtmauer, E. A. ; Tay, J. ; To, L. B. ; Vesole, D. H. ; Vogl, D. T. ; Wagner, J. L. ; Wirk, B. ; Wood, W. A. ; D'Souza, A. / Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. In: Bone marrow transplantation. 2015 ; Vol. 50, No. 12. pp. 1513-1518.
@article{d18dfcbea0cc4d4dae1175a76f7583ca,
title = "Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation",
abstract = "In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43{\%} (95{\%} confidence interval (CI) 38-48) in GF and 40{\%} (95{\%} CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82{\%} (95{\%} CI 78-86) vs 80{\%} (95{\%} CI 75-84), P=0.43 and adjusted 5-year OS was 62{\%} (95{\%} CI 54-68) vs 60{\%} (95{\%} CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.",
author = "Uy, {G. L.} and Costa, {L. J.} and Hari, {P. N.} and Zhang, {M. J.} and Huang, {J. X.} and Anderson, {K. C.} and Bredeson, {C. N.} and Callander, {N. S.} and Cornell, {R. F.} and Perez, {M. A.D.} and A. Dispenzieri and Freytes, {C. O.} and Gale, {R. P.} and A. Garfall and Gertz, {M. A.} and J. Gibson and M. Hamadani and Lazarus, {H. M.} and Kalaycio, {M. E.} and Kamble, {R. T.} and Kharfan-Dabaja, {M. A.} and Krishnan, {A. Y.} and Kumar, {S. K.} and Kyle, {R. A.} and Landau, {H. J.} and Lee, {C. H.} and A. Maiolino and Marks, {D. I.} and Mark, {T. M.} and R. Munker and T. Nishihori and Olsson, {R. F.} and M. Ramanathan and Rodriguez, {T. E.} and Saad, {A. A.} and Savani, {B. N.} and Schiller, {G. J.} and Schouten, {H. C.} and Schriber, {J. R.} and Emma Scott and S. Seo and M. Sharma and S. Ganguly and Stadtmauer, {E. A.} and J. Tay and To, {L. B.} and Vesole, {D. H.} and Vogl, {D. T.} and Wagner, {J. L.} and B. Wirk and Wood, {W. A.} and A. D'Souza",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/bmt.2015.190",
language = "English (US)",
volume = "50",
pages = "1513--1518",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

AU - Uy, G. L.

AU - Costa, L. J.

AU - Hari, P. N.

AU - Zhang, M. J.

AU - Huang, J. X.

AU - Anderson, K. C.

AU - Bredeson, C. N.

AU - Callander, N. S.

AU - Cornell, R. F.

AU - Perez, M. A.D.

AU - Dispenzieri, A.

AU - Freytes, C. O.

AU - Gale, R. P.

AU - Garfall, A.

AU - Gertz, M. A.

AU - Gibson, J.

AU - Hamadani, M.

AU - Lazarus, H. M.

AU - Kalaycio, M. E.

AU - Kamble, R. T.

AU - Kharfan-Dabaja, M. A.

AU - Krishnan, A. Y.

AU - Kumar, S. K.

AU - Kyle, R. A.

AU - Landau, H. J.

AU - Lee, C. H.

AU - Maiolino, A.

AU - Marks, D. I.

AU - Mark, T. M.

AU - Munker, R.

AU - Nishihori, T.

AU - Olsson, R. F.

AU - Ramanathan, M.

AU - Rodriguez, T. E.

AU - Saad, A. A.

AU - Savani, B. N.

AU - Schiller, G. J.

AU - Schouten, H. C.

AU - Schriber, J. R.

AU - Scott, Emma

AU - Seo, S.

AU - Sharma, M.

AU - Ganguly, S.

AU - Stadtmauer, E. A.

AU - Tay, J.

AU - To, L. B.

AU - Vesole, D. H.

AU - Vogl, D. T.

AU - Wagner, J. L.

AU - Wirk, B.

AU - Wood, W. A.

AU - D'Souza, A.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

AB - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥0.5 × 10 9 /L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (≥20 × 10 9 /L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

UR - http://www.scopus.com/inward/record.url?scp=84949085500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949085500&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.190

DO - 10.1038/bmt.2015.190

M3 - Article

C2 - 26301967

AN - SCOPUS:84949085500

VL - 50

SP - 1513

EP - 1518

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -